Deals Report: Delivery play Nuntius out of stealth with Taiho cancer deal

During a slow week for deal-making overall, U.K.-based Nuntius Therapeutics Ltd. emerged from stealth with its announcement of a partnership with Taiho Pharmaceutical Co. Ltd., giving the Japanese pharma access to its cell-specific delivery technology for use in mRNA cancer immunotherapies.

Nuntius has revealed fairly little about itself thus far, although its announcement of the Taiho deal described peptide dendrimer- and lipid-based nanocarriers. The approach is one of many that have emerged as alternatives to adeno-associated viral (AAV) or lipid nanoparticle (LNP) delivery of genetic material to specific tissues while avoiding immunogenicity...